User login

Enter your username and password here in order to log in on the website:

vwd up-to-date–
news, dates, events



Migration to the current vwd portfolio manager Version 6
Product training

Tuesday, 30 April 2019, 10:00 - 11:00 CEST

The webinar will be held in German.


Presentation of the most important changes and new features of the current version of vwd portfolio manager 6.30 and migration from version 4.xx

  • Portfolio functionalities
  • Securities (data retention)
  • Performance calculation
  • Alerting (e.g. for monitoring customer portfolios)
  • pm server for job control
  • Batch export and reporting
  • Usability
  • Document filing
  • Audit safety

Target group

The webinar is aimed at vwd portfolio manager users.

There are no costs for participating the webinar.
DKF 2019, 9. D-A-CH Kongress für Finanzinformationen
Exhibitions and Congresses

"Accelerating growth through innovative technology"
How to successfully implement the newest Fintech solutions

The D-A-CH congress for financial information 2019 (DKF 2019) brings decision makers, solution providers and experts from the financial service sector together.

The conference part of the DKF consists of four thematic streams:

  • Market Data Products & Solutions
  • Reference Data Management & Feeds
  • Investment & Portfolio Management Trends
  • FinTech offerings & technological developments

Two exhibition levels will offer 40 exhibitors the option to present solutions and current developments concerning trading platforms, asset management systems, risk management solutions, applications and technologies to key users, IT managers and market data leaders of the finance industry.

We would be pleased to advise you in detail on our modular solution offer. Visit us at the vwd stand: P2, Nymphenburg.

Please also note the presentation of our colleague, Christian Kulnick, Associate Director Product Management: “Realtime Investmentmanagement & Controlling”,  Speakerslot C1, 10:00-10:30 h.

Further information can be found on the official DKF 2019 website

Exhibitions and Congresses

Every year more than 11,000 students use konaktiva to get closer to an internship, a working student position and even their dream job.

Come by on 08.05.2019 at booth B7 and get to know us! You are also welcome to make an appointment with us in advance. Please contact Stefanie Blasi by mail.

08. May 2019, 09:30 - 16:30 o'clock

darmstadtium (Science and Congress Centre), Schloßgraben 1, 64283 Darmstadt, Germany

Students of all disciplines and universities

Visiting the fair is free of charge and does not require registration. The konaktiva is organised by a team of volunteer students.

Digital processes for asset management
Product training

Thursday, 9 May 2019, 10:00 - 11:00 CEST

The webinar will be held in German.


In this webinar we will show you how you can use the vwd advisory solution in conjunction with the vwd portfolio manager and the associated services to implement your own processes digitally more easily and efficiently in the future.

Based on the VuV sample documents, we provide you with the following standard processes, which we would like to present to you during the webinar:

  • Customer profiling (WpHG)
  • Offer preparation Asset management
  • Preparation of contracts (model contracts VuV)

Target group

This webinar is aimed at users of the vwd portfolio manager and vwd advisory solutionb.

There are no costs for participating the webinar.
Treffpunkt Kaiserslautern
Exhibitions and Congresses

Motivated graduates and students of all disciplines from universities and universities of applied sciences from all over southwest Germany have the opportunity to get to know what the vwd has to offer and make their first contacts at the meeting point company contact fair in Kaiserslautern.

You will find us from 10.00 to 16.00 in building 42 of the TU Kaiserslautern. You are also welcome to arrange an appointment with us in advance. Please send an e-mail to Sandra Schintu.

All dates



 Latest news on markets, economy and companies


Business Wire



05.02.2019 Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan

Idorsia Pharmaceuticals Ltd. /

Idorsia announces the first patient recruited into REACT - the Phase 3

registration study with clazosentan

. Verarbeitet und übermittelt durch West Corporation.

Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

Source: Globenewswire

  • REACT assesses the efficacy and safety of intravenous clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage (aSAH)

  • On June 18, 2018, Idorsia announced the plans for REACT and held an investor webcast, please refer to the documentation on our corporate website for more information

Allschwil, Switzerland - February 5, 2019
Idorsia Ltd (SIX: IDIA) today announced that the first patient has been included into REACT, a Phase 3 registration study to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage.

Guy Braunstein, MD and Head of Global Clinical Development, commented:
'REACT builds on the learnings from previous clinical studies with clazosentan, which have served to identify the optimal treatment dose for Phase 3 evaluation and the characteristics and management of the patients that are most likely to benefit from this treatment. It is very satisfying to have achieved the milestone of first patient included into the study. It's now full steam ahead to recruit 400 patients.'

Notes to the editor

About clazosentan
Several studies have built our understanding of clazosentan, an intravenous endothelin receptor antagonist, regarding its impact on preventing or reversing cerebral vasospasm. These studies suggest that clazosentan has the potential to prevent vasospasm-related delayed cerebral ischemia and to decrease the need for invasive neurovascular intervention. Clazosentan was granted orphan status in Europe in 2003 and in the US in 2006.

About the REACT study
REACT is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to vasospasm-related delayed cerebral ischemia, in adult patients with aSAH. Approximately 400 patients, regardless of whether their hemorrhage has been treated with surgical clipping or endovascular coiling are expected to be enrolled. Patients will be enrolled from 100 trial sites across 15 countries and will be randomized to either 15 mg/hr clazosentan or placebo for a treatment period of up to 14 days. The study is expected to run for over two years.

REACT will enroll aSAH patients identified as being at high-risk of developing delayed ischemic neurological deficit because of high volume of their hemorrhage, as assessed by CT scan on hospital admission. Patients experiencing asymptomatic (or minimally symptomatic) moderate to severe cerebral vasospasm within 14 days of the aneurysm-rupture may also be included.

About aneurysmal subarachnoid hemorrhage and cerebral vasospasm
Aneurysmal subarachnoid hemorrhage (aSAH) is a sudden life-threatening bleeding occurring in the subarachnoid space. It is caused by the rupture of an aneurysm - a weak, bulging spot on the wall of a cerebral artery. Emergency repair (endovascular coiling or microsurgical clipping) is required to stop the hemorrhage.

The bleeding and the release of a vasoconstrictor, endothelin, by the neighboring vascular endothelium, causes many patients to experience vasospasm (constriction of arteries in the brain). This diminishes blood flow to the brain and as a consequence, about one third of patients experience worsening of their neurological condition. Patients with thick and diffuse blood clots are at a significantly higher risk of experiencing cerebral vasospasm. Today, patients with vasospasm are typically treated with hemodynamic therapy, or more invasive neurovascular intervention such as balloon angioplasty or intra-arterial administration of vasodilators.


  • Macdonald R L, et al. Stroke. 2012; 43(6):1463-9.

  • Macdonald R L, et al. The Lancet. Neurology, 2011; 10(7):618-625.

  • Macdonald R L, et al. Stroke 2008; 39:3015-3021.

  • Vajkoczy P, et al. Journal of Neurosurgery 2005; 103:9-17.

  • Roux S. et al. J Pharmacol Exp Ther 1997; 283:1110-1118.

About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core.

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet - the ideal constellation to bringing R&D efforts to business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 700 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10

The above information contains certain 'forward-looking statements', relating to the company's business, which can be identified by the use of forward-looking terminology such as 'estimates', 'believes', 'expects', 'may', 'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks', 'pending' or 'anticipates' or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Idorsia Pharmaceuticals Ltd. via Globenewswire

--- Ende der Mitteilung ---

Idorsia Pharmaceuticals Ltd.
Hegenheimermattweg 91 Allschwil Schweiz

ISIN: CH0363463438;


Subscribe to our free newsletter and you will receive the latest information about our products and solutions.








vwd Vereinigte Wirtschaftsdienste GmbH
Mainzer Landstrasse 178 – 190
60327 Frankfurt am Main

Phone: +49 69 50701-0
E-mail: dialogue(at)



Your questions will be answered by
Christiane Kaczmarek-Schempp.

Phone: +49 69 50701-286
E-mail: ckaczmarek(at)

Xing  LinkedIn  facebook  Twitter